[go: up one dir, main page]

MX343669B - Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1. - Google Patents

Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1.

Info

Publication number
MX343669B
MX343669B MX2013005471A MX2013005471A MX343669B MX 343669 B MX343669 B MX 343669B MX 2013005471 A MX2013005471 A MX 2013005471A MX 2013005471 A MX2013005471 A MX 2013005471A MX 343669 B MX343669 B MX 343669B
Authority
MX
Mexico
Prior art keywords
inhibitors
kinase
combination
wee
checkpoint
Prior art date
Application number
MX2013005471A
Other languages
English (en)
Other versions
MX2013005471A (es
Inventor
Kurtis D Davies
Stefan Gross
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2013005471A publication Critical patent/MX2013005471A/es
Publication of MX343669B publication Critical patent/MX343669B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una combinación de un inhibidor CHK1 y un inhibidor WEE1.
MX2013005471A 2010-11-16 2011-11-16 Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1. MX343669B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41433710P 2010-11-16 2010-11-16
US201161454488P 2011-03-18 2011-03-18
PCT/US2011/060998 WO2012074754A1 (en) 2010-11-16 2011-11-16 Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2013005471A MX2013005471A (es) 2013-09-02
MX343669B true MX343669B (es) 2016-11-16

Family

ID=45217677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005471A MX343669B (es) 2010-11-16 2011-11-16 Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1.

Country Status (12)

Country Link
US (2) US9370567B2 (es)
EP (1) EP2640386B1 (es)
JP (2) JP6091422B2 (es)
KR (1) KR101884960B1 (es)
CN (2) CN108721284A (es)
BR (1) BR112013011918A2 (es)
CA (1) CA2817968C (es)
ES (1) ES2621857T3 (es)
MX (1) MX343669B (es)
RU (2) RU2017127088A (es)
TW (1) TW201304778A (es)
WO (1) WO2012074754A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959887B (zh) 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
MX343669B (es) 2010-11-16 2016-11-16 Array Biopharma Inc Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1.
US9345705B2 (en) * 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
SMT202100425T1 (it) 2012-12-07 2021-09-14 Vertex Pharma 2-ammino-n-(piperidin-1-il-piridin-3-il) pirazolo[1,5alpha]piirimidina-3-carbossiammide come inibitore di atr chinasi
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
WO2014188201A2 (en) * 2013-05-22 2014-11-27 Cancer Research Technology Limited Treatment
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
WO2015183776A1 (en) * 2014-05-29 2015-12-03 Merck Sharp & Dohme Corp. Methods for treating cancer with a wee1 inhibitor
SI3152212T1 (sl) 2014-06-05 2020-06-30 Vertex Pharmaceuticals Inc. Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike
SG10201811175WA (en) * 2014-06-17 2019-01-30 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
US10449197B2 (en) 2015-07-01 2019-10-22 Dignity Health Systems and methods for treating cancer
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
AR106772A1 (es) * 2015-12-07 2018-02-14 Lilly Co Eli Sales de (s)-lactato
CA3005358A1 (en) * 2015-12-15 2017-06-22 Eli Lilly And Company Combination therapy for cancer
CN108601781B (zh) * 2016-02-04 2019-11-22 广州必贝特医药技术有限公司 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
SG11201908788YA (en) * 2017-03-31 2019-10-30 Seattle Genetics Inc Combinations of chk1- and wee1 - inhibitors
CN110582490A (zh) * 2017-04-10 2019-12-17 塞拉肿瘤学公司 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法
WO2018191299A1 (en) * 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
RU2020126774A (ru) * 2018-01-12 2022-02-14 ПРОЛИНКС ЭлЭлСи Протокол для сведения к минимуму токсического воздействия комбинированных доз и визуализирующий агент для подтверждения
US12295938B2 (en) 2019-06-04 2025-05-13 Samsung Life Public Welfare Foundation Composition for treating castration-resistant prostate cancer, comprising quassinoids
CN110585435B (zh) * 2019-09-25 2022-04-01 香港浸会大学深圳研究院 具有抗癌效果的组合物及其应用
EP4422624A4 (en) * 2021-10-28 2025-12-03 Recurium Ip Holdings Llc POLYTHERAPIES INCLUDING WEE1 INHIBITORS AND DNA DAMAGE RESPONSE (DDR) INHIBITORS

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
EP1523485B1 (en) 2002-07-15 2007-02-14 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
US20050037476A1 (en) 2003-05-29 2005-02-17 Pfizer Inc Modified Wee1, crystals of peptide: inhibitor complexes containing such modified Wee1, and methods of use thereof
EP1667684A1 (en) * 2003-09-17 2006-06-14 ICOS Corporation Use of chk1 inhibitors to control cell proliferation
DE602004031777D1 (en) 2004-01-05 2011-04-21 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
AU2006232620A1 (en) 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
WO2007113671A1 (en) 2006-04-04 2007-10-11 Pfizer Products Inc. Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
CA2669982A1 (en) 2006-11-17 2008-05-29 Schering Corporation Combination therapy for proliferative disorders
EA200901138A1 (ru) 2007-03-20 2010-04-30 Смитклайн Бичем Корпорейшн Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EP2136632A4 (en) 2007-03-20 2011-01-19 Glaxosmithkline Llc CHEMICAL COMPOUNDS
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
CN101959887B (zh) 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
WO2009151598A1 (en) 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
EP2324024B1 (en) 2008-06-11 2012-09-26 Genentech, Inc. Diazacarbazoles and methods of use
EP2376493B1 (en) 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
WO2010098367A1 (en) 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Pyrimidopyrimidoindazole derivative
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
RU2567044C2 (ru) * 2009-04-11 2015-10-27 Эррэй Биофарма Инк. Ингибиторы 1 киназы контрольной точки клеточного цикла для усиления днк-повреждающих агентов
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
MX343669B (es) 2010-11-16 2016-11-16 Array Biopharma Inc Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1.

Also Published As

Publication number Publication date
BR112013011918A2 (pt) 2020-08-25
RU2627841C2 (ru) 2017-08-14
KR20130114181A (ko) 2013-10-16
RU2017127088A (ru) 2019-02-04
JP6091422B2 (ja) 2017-03-08
EP2640386B1 (en) 2017-01-18
JP2013542997A (ja) 2013-11-28
US9370567B2 (en) 2016-06-21
US10434094B2 (en) 2019-10-08
TW201304778A (zh) 2013-02-01
KR101884960B1 (ko) 2018-08-30
CN108721284A (zh) 2018-11-02
US20130231301A1 (en) 2013-09-05
CN103442710A (zh) 2013-12-11
WO2012074754A1 (en) 2012-06-07
ES2621857T3 (es) 2017-07-05
US20160375002A1 (en) 2016-12-29
JP2017014291A (ja) 2017-01-19
CA2817968C (en) 2019-03-12
RU2013127323A (ru) 2014-12-27
MX2013005471A (es) 2013-09-02
CN103442710B (zh) 2018-05-29
EP2640386A1 (en) 2013-09-25
CA2817968A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
MX343669B (es) Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1.
AU333421S (en) Showerhead
WO2012158843A3 (en) Kinase inhibitors
MX338327B (es) Inhibidores de cdk.
IN2015DN03795A (es)
CR20140024A (es) Compuestos inhibidores de metaloenzimas
UY33930A (es) Inhibidores novedosos de quinasas
UY33958A (es) Inhibidores de la glucosilceramida sintasa
PH12016500895A1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
MX337869B (es) Articulos retrorreflejantes que incluyen marca de seguridad.
UY34666A (es) Inhibidores de quinasa a base de ariléter
MX336025B (es) Inhibidor de suciedad para zapato y sus métodos de fabricación.
MX337870B (es) Articulos retrorreflejantes que incluyen marca de seguridad.
MX2015008813A (es) Composiciones y metodos para contrarrestar la inhibicion del factor xa.
MX336865B (es) Imidazopiridazinas como inhibidores de quinasa akt.
IN2013DN02552A (es)
GB201211120D0 (en) Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
UY34800A (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa-1 útil en trastornos metabólicos
EP3443613B8 (en) Subsea uninterruptible power supply
MX393754B (es) Metodos y composiciones para inhibir cnksr1
EP2604606A4 (en) INHIBITORS OF CASEIN KINASE 1 AND CASEIN KINASE 1
MY189843A (en) Anti-agglomerate hydrate inhibitors
UA52529U (ru) Применение уретроскопа комбинированного (модель 513) как троакарной системы для эпицистостомии
AU335913S (en) A coulter disc
PL393134A1 (pl) Inhibitor do ochrony antykorozyjnej rurociągów gazowych

Legal Events

Date Code Title Description
FG Grant or registration